Third-line gemcitabine monotherapy for platinum-resistant advanced urothelial cancer

International Journal of Clinical Oncology

Volumn 15, Issue 4, 2010, Pages 376-381

  Soga, Norihito ^a   Kise, Hideaki ^a   Arima, Kiminobu ^a   Sugimura, Yoshiki ^a  

^a MIE UNIVERSITY   (Japan)

Author keywords

Gemcitabine; Platinum resistant urothelial cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; GEMCITABINE; METHOTREXATE; PACLITAXEL; PLATINUM COMPLEX; VINBLASTINE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLADDER CANCER; BONE MARROW SUPPRESSION; BONE METASTASIS; CANCER GROWTH; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTECTOMY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; LIVER DYSFUNCTION; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROURETERECTOMY; NEUTROPENIA; OVERALL SURVIVAL; PELVIS TUMOR; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; URETER TUMOR; UROGENITAL TRACT CANCER; VISCERAL METASTASIS; VOMITING;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; UROLOGIC NEOPLASMS; UROTHELIUM;

EID: 77955708928     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-010-0071-8     Document Type: Article

References (22)

1. Saxman SB, Propert KJ, Einhorn LH et al (1997) Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol 15:2564-2569
2. von der Maase H, Sengelov L, Roberts JT et al (2005) Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23:4602-4608
3. Rosenberg JE, Caroll PR, Small FJ (2005) Update on chemotherapy for advanced bladder cancer. J Urol 174:14-20
4. Pycha A, Grbovic M, Posch B et al (1999) Paclitaxel and carboplatin in patients with metastatic transitional cell cancer of the urinary tract. Urology 53:510-515 (Pubitemid 29136194)
5. Sweeney CJ, Williams SD, Finch DE et al (1999) A phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium. Cancer (Phila) 86:514-518
6. Tu SM, Hossan E, Amato R et al (1995) Paclitaxel, cisplatin and methotrexate combination chemotherapy is active in the treatment of refractory urothelial malignancies. J Urol 154:1719-1722
7. Sternberg CN, Calabro F, Pizzocaro G et al (2001) Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer (Phila) 92:2993-2998
8. Soga N, Onishi T, Arima K et al (2007) Paclitaxel carboplatin chemotherapy as a second-line chemotherapy for advanced platinum resistant urothelial cancer in Japanese cases. Int J Urol 14:828-832
9. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
10. Meluch AA, Greco FA, Burris HA 3rd et al (2001) Paclitaxel and gemcitabine. J Clin Oncol 19:3018-3024
11. Krege S, Rembrink V, Borgermann C et al (2001) Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: A phase 2 study. J Urol 165:67-71
12. Vaughn DJ, Broome CM, Hussain M (2002) Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol 20:937
13. Pectasides D, Aravantinos G, Kalofonos H et al (2001) Combination chemotherapy with gemcitabine and ifosfamide as secondline treatment in metastatic urothelial cancer. A phase II trial conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 12:1417-1422
14. Pollera CF, Ceribelli A, Crecco M et al (1994) Weekly gemcitabine in advanced bladder cancer: A preliminary report from a phase I study. Ann Oncol 5:182-184 (Pubitemid 24062575)
15. von der Maase H (2000) Gemcitabine in locally advanced and/or metastatic bladder cancer. Crit Rev Oncol Hematol 34:175-183
16. Stadler WM, Kuzel T, Roth B et al (1997) Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 15:3394-3398
17. Moore MJ, Tannock IF, Ernst DS et al (1997) Gemcitabine: A promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 15:3441-3445
18. Gebbia V, Testa A, Borsellino N et al (1999) Single agent 20,20- difluorodeoxycytidine in the treatment of metastatic urothelial carcinoma: A phase II study. Clin Ter 150:11-15
19. Lorusso V, Pollera CF, Antimi M et al (1998) A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur J Cancer 34:1208-1212
20. Albers P, Siener R, Hartlein M et al (2002) Gemcitabine monotherapy as second-line treatment in cisplatin-refractory transitional cell carcinoma-prognostic factors for response and improvement of quality of life. Onkologie 25:47-52
21. Akaza H, Naito S, Usami M et al (2007) Efficacy and safety of gemcitabine monotherapy in patients with transitional cell carcinoma after cisplatin-containing therapy: A Japanese experience. Jpn J Clin Oncol 37:201-206
22. Ecke TH, Gerullis H, Bartel P et al (2009) Palliative chemotherapy with gemcitabine, paclitaxel, and cisplatin as first-line treatment following gemcitabine monotherapy for patients with transitional cell carcinoma of the urothelium. Minerva Urol Nefrol 61:1-8